Antiangiogenics: new therapeutic standards in metastatic kidney cancer

被引：5

作者：

Cornu, J. -N. ^{[2
]}

Roupret, M. ^{[2
]}

Bensalah, K. ^{[1
]}

Oudard, S. ^{[3
]}

Patard, J. -J. ^{[1
]}

机构：

[1] CHU Rennes, Serv Urol, F-35033 Rennes, France

[2] Univ Paris 06, Fac Med Pierre & Marie Curie, Grp Hosp Univ Est, Assistance Publ Hop Paris,Serv Urol,Hop Pitie Sal, Paris, France

[3] HEGP, Med Oncol Serv, F-75908 Paris 15, France

来源：

PROGRES EN UROLOGIE | 2008年 / 18卷

关键词：

receptor tyrosine kinase inhibitor; renal cell carcinoma; sorafenib; suniti; temsi olimus; bevacizumab;

D O I：

10.1016/S1166-7087(08)73665-0

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Since 2004, the treatment of metastatic renal cell carcinoma is in deep mutation. Before, the Management was mostly relying on the use of cytokines in association with radical nephrectomy. From 2004, studies of new antiangiogenic molecules, acting on the pVHL-HIF way, VEGF, PDGF or tyrosine-kinase receptors have modified the management of metastatic patients. Antiangiogenic agents improve progression-free survival as shown with sunitinib, in first tine treatment, or sorafenib, as second tine treatment. The m-TOR inhibitors (Temsirolimus), can be used with a benefit on overall survival in case of poor prognosis renal, cell. carcinoma or non clear cell carcinoma. Lastly, bevacizumab, an antibody re-combining humanized monoclonal, is able to target VEGF. Side effects are different for each molecule and are not negligible. Nevertheless, the place of these molecules have to be defined in the sequence of the treatment. (C) 2008 Elsevier Masson SAS. Tous droits reserves.

引用

页码：S69 / S76

页数：8

共 33 条

[1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[2] Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity [J].

Blankenship, C ;

Naglich, JG ;

Whaley, JM ;

Seizinger, B ;

Kley, N .

ONCOGENE, 1999, 18 (08) :1529-1535

[3] Protein kinase inhibitors in the treatment of renal cell carcinoma:: sorafenib [J].

Bracarda, S. ;

Caserta, C. ;

Sordini, L. ;

Rossi, M. ;

Hamzay, A. ;

Crino, L. .

ANNALS OF ONCOLOGY, 2007, 18 :22-25

[4]

Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154

[5] Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein [J].

Cockman, ME ;

Masson, N ;

Mole, DR ;

Jaakkola, P ;

Chang, GW ;

Clifford, SC ;

Maher, ER ;

Pugh, CW ;

Ratcliffe, PJ ;

Maxwell, PH .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25733-25741

[6] Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: Overview of recent clinical trials differentiating clinical response and adverse effects [J].

Dreicer, Robert .

CLINICAL GENITOURINARY CANCER, 2006, 5 :S19-S23

[7]

Escudier Bernard, 2007, Prog Urol, V17, P150

[8] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[9]

Fergelot P, 2005, PROG UROL, V15, P1021

[10] MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA [J].

GNARRA, JR ;

TORY, K ;

WENG, Y ;

SCHMIDT, L ;

WEI, MH ;

LI, H ;

LATIF, F ;

LIU, S ;

CHEN, F ;

DUH, FM ;

LUBENSKY, I ;

DUAN, DR ;

FLORENCE, C ;

POZZATTI, R ;

WALTHER, MM ;

BANDER, NH ;

GROSSMAN, HB ;

BRAUCH, H ;

POMER, S ;

BROOKS, JD ;

ISAACS, WB ;

LERMAN, MI ;

ZBAR, B ;

LINEHAN, WM .

NATURE GENETICS, 1994, 7 (01) :85-90

← 1 2 3 4 →